Catalog No.
VMD17204
Species reactivity
Mouse
Host species
Mouse
Isotype
IgG
Clonality
Monoclonal
Target
Bispecific, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, Ctla4, Cd152, Tumor necrosis factor receptor superfamily member 4, OX40 antigen, OX40L receptor, CD134, Tnfrsf4, Ox40, Txgp1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P09793 & P47741
Applications
FuncS
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0227
Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?, PMID:40536609
Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells., PMID:40536473
Palmitoylation-driven immune dysregulation and prognostic signature in low-grade glioma: a multi-omics and functional validation study., PMID:40535771
F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies., PMID:40534867
Immunolocalization of CD28, CTLA-4 and CD80 in Non-Small Cell Lung Carcinoma: Combined CD28/CTLA-4/CD80 Status is a Potent Prognostic Factor of These Patients., PMID:40533179
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis., PMID:40532761
Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion., PMID:40532063
An evaluation of Nivolumab and ipilimumab for the treatment of resectable stage III melanoma., PMID:40531544
Identification of CENPW as a prognostic biomarker and potential therapeutic target for clear cell renal cell carcinoma., PMID:40531390
Seven Hypoxia and Immune-Related Features Predict Prognosis in Patients with Hepatocellular Carcinoma., PMID:40531258
The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study., PMID:40529375
The next generation of immunotherapies for lung cancers., PMID:40528044
Spatial Transcriptomic Landscape of Canine Oral Squamous Cell Carcinoma., PMID:40525754
Systematic Pan-Cancer Analysis of the Oncogenic and Immunological Function of Stanniocalcin-1 (STC1)., PMID:40525442
Radiation-Based Multi-Modal Therapy Combining with Immunotherapy to Develop a Vaccine-Like Effective Treatment for Triple-Negative Breast Cancer., PMID:40524764
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis., PMID:40523912
Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study., PMID:40521168
Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human., PMID:40518289
T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors., PMID:40517973
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma., PMID:40514309
Advanced biomaterials for the targeted delivery of immune checkpoint inhibitors to solid tumors., PMID:40513669
Emerging Immunotherapy Targets in Early Drug Development., PMID:40508202
Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations., PMID:40508177
Impaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-Analysis., PMID:40507352
Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data., PMID:40507314
Advances in drug treatments for male patients with prolactinomas., PMID:40505642
Association between CTLA4-658C>T Polymorphism and Colorectal Cancer in Medan, Indonesia., PMID:40504777
High antigen burden drives CD8+ T cell dysfunction in a mouse model of chronic hepatitis B virus infection., PMID:40503880
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution., PMID:40503235
NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies., PMID:40502306
SGSM1 as a pan-cancer biomarker: multi-omics insights into immune regulation, prognostic value, and therapeutic implications., PMID:40500484
Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy., PMID:40499464
Role of Ischemia/Reperfusion and Oxidative Stress in Shock State., PMID:40497985
The dual role of TIGIT in regulatory and effector T cells in chronic liver disease., PMID:40496440
Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer., PMID:40492347
Harnessing the Power of Chlorogenic Acid: Inhibiting IL-2-Mediated Treg Upregulation to Combat Post-Traumatic Osteomyelitis., PMID:40485518
Pregnancy-associated thyroid disorders: the role of genetic, epigenetic, and oxidative stress factors., PMID:40484893
Serum PD-L1 and CTLA-4 levels as biomarkers of acute rejection and renal dysfunction in kidney transplant recipients., PMID:40482974
Dual blockade of PD-1 and CTLA-4 generates long-lasting immunity against irradiated glioblastoma., PMID:40482909
CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies., PMID:40482550
Immunohistochemical expression of PD1, LAG3, and CTLA4 in diffuse large B cell lymphoma, clinicopathological correlation, and prognostic value., PMID:40481915
The immunosurveillance signature predicts the prognosis and immunotherapy sensitivity for colon adenocarcinoma., PMID:40481062
Targeting B and T lymphocyte attenuator in cancer immunotherapy., PMID:40480574
Co-regulation of miRNA and lncRNA on immunosuppression gene: unveiling the regulatory networks in cancer., PMID:40479646
Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?, PMID:40476645
Comprehensive evaluation of clinical phenotypes and pathogenic features in late-onset monogenic inflammatory bowel disease: a comparative study with infantile-onset cases., PMID:40474095
Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance., PMID:40473819
Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy., PMID:40469104
CTLA4 Single-Nucleotide Polymorphisms Influence the Risk of HSV and VZV Infection in Kidney Transplant Recipients: A Prospective Cohort Study., PMID:40469083
Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755
For research use only. Not for human or drug use.
